NCI Division of Cancer Prevention shared a post on LinkedIn:
“This JNCI paper reports the results of an evaluation of multi-cancer detection (MCD) assays for the Cancer Screening Research Network (CSRN) Vanguard Study using a high-quality reference set (blood samples from patients with and without cancer).
Funded by the The National Institutes of Health, National Cancer Institute (NCI), the Alliance for Clinical Trials in Oncology reference set study (NCT05334069) used a standardized, blinded approach to assess six MCD assays in the same study population, covering various cancer types and controls.”
Title: Performance of multiple multi-cancer detection tests using a large independent reference set (Alliance A212102)
Authors: Marie Wood, Paul F Pinsky, Paul Novotny, Elyse Leevan, Matthias Weiss, Dan C Edelman, Mark Watson, Christos Patriotis, Jason D Merker, Philip C Prorok, Yujia Wen, Wendy S Rubinstein, Konstantin Dragnev, Amanda L Skarlupka, Hormuzd A Katki, Selina Chow, Margaret Kemeny, Umang Gautam, Aswanth Reddy, William Burak, Steven Piantadosi, Lori M Minasian
Read the Full Article.
Other articles from NCI Division of Cancer Prevention.